The vision to change the world
Life–changing therapy by global leaders in ophthalmology
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.
Patented childhood myopia control therapy
Eyerising International’s Myopia Management Repeated Low-Level Red–Light (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.
View our most important scientific papers
A 12-month clinical trial conducted on 264 participants published on Ophthalmology
24-month follow-up clinical trial conducted on 199 participants published on CEO
Clinical trial to assess the efficacy and safety of treatment in controlling myopia progression compared to a sham device with only 10% of the original power published on Ophthalmology
A multicenter, randomized controlled trial (RCT) to evaluate longitudinal changes in macular choroidal thickness in myopic children treated for one year with the treatment published on Ophthalmology
Clinically Significant Axial Shortening in Myopic after RLRL
Axial Shortening in Myopic Children after Repeated Low-Level Red-Light Therapy
News and press releases
Revolutionary Landmark Study on Repeated Low-Level Red-Light (RLRL) Therapy and Orthokeratology Published!
The findings promise to revolutionize how we approach myopia treatment , offering new hope to patients with myopia worldwide. Kudos to the dedicated research team for their hard work Read more here >
A response to ‘Red light instruments for myopia exceed safety limits’
John Battersby First published: 01 March 2024 To the Editor, Paul Cooke, the CEO of Eyerising International, an Australian company that is the legal manufacturer of a Repeated Low-Level Red-Light device, would appreciate an opportunity[...]
Eyerising International Refute Inaccurate Claims in OPO Article
Eyerising International list multiple errors and inaccuracies in the article: • The authors incorrectly alleged the Eyerising device did not meet safety standards it claimed • The authors tested devices to the wrong ANSI standards[...]
Daring Descents For A Cause: Eyerising International Sponsors Young Adventurers At The Brighton i360 Experience
An unforgettable adventure unfolded as young thrill-seekers, Ella (17) and Tegan Hemming (15), took on the iconic i360 experience in Brighton. This adrenaline-pumping descent from a towering structure was not only a test of courage[...]
Myopia: Repeated low-level red-light therapy
Bill Harvey hears about a new, light-based myopia management treatment that is proving popular in Australia and likely to make an impact in the UK in the coming years. Read the full article >
Repeated Low-Level Red-Light Therapy Presents Exciting New Possibility in the Fight Against Myopia
Repeated low-level red-light (RLRL) therapy, now available through a medical device, could potentially change the treatment landscape for myopia and save billions of eyes from sight-threatening conditions in future. Read the full article >
Professor Mingguang He
Founder, Chief Medical Officer
Prof. He has over 25 years of experience in ophthalmology. He is currently a Professor of Ophthalmic Epidemiology at the University of Melbourne and leads ophthalmic epidemiology research at the Centre for Eye Research Australia. His research has led to original articles and invited editorials in respected medical journals, including the Journal of the American Medical Association, Diabetes Care, & Ophthalmology.
Jason Sun
Founder, MD
With a clinical background and over 20+ years of executive experience in the Australian health sector, including 10 years of industry development experience, Mr. Sun brings expertise in Medtech commercialisation, international business, regulatory compliance, and government relations.
Michael Woods
Executive Director
Mr. Woods has been an investor, adviser, board member, and CEO for various life science start-ups and scale-up companies in the life sciences sector.
Manny Pascual
Head of Commercial
Over 20 years of experience in the medical device industry Previous Marketing Director for CooperVision Asia Pacific Previous success in medical device company business expansion and acceleration.
David Holland
Business Development Manager (Australasia)
Federico Roma
CTO Accomplished technology leader
Dr. Yuri Aung
Clinical Affairs and RAQA Manager
Dr. Lisa Zhuoting Zhu
Director of Clinical Development
For any investor questions, please send your queries to:
Email: info@eyerisinginternational.com
Eyerising International Pty Ltd
Head office
Suite 2.05
9/11 Claremont St
South Yarra VIC 3141
